reports
- Dr Dennis Hulme
TruScreen - Fast and objective cervical cancer screening
TruScreen is focused on the effective commercialisation of its second-generation TruScreen2 optoelectronic cervical cancer screening device, which has already been launched in key target markets. The device provides objective and real-time cervical cancer screening assessments and requires only limited training for the operator, which makes it well-suited for developing countries.
Comment: New Zealand talks tech September 2015
truScreen (TRU) manufactures and distributes a unique testing device that detects cancerous and pre-cancerous cells in the cervix. The developing world, which has the highest incidence and mortality from cervical cancer, is the target market. TRU, which listed on the NZX in November 2014, has secured China Food and Drug Administration (CFDA) approval to market TruScreen in China, where there is no cervical cancer testing regime and a potential market of 388 million.
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.